Synchron Pauses Stentrode Brain-Computer Interface Trial Enrollment Over Lead Performance Issue
Endovascular brain-computer interface developer Synchron has voluntarily paused enrollment in clinical trials of its second-generation wireless Stentrode implant after identifying a performance problem with the lead connecting the blood-vessel electrode array to the implanted electronics, Inside BCI and The World of Implantable Devices reported on November 13, 2026, citing a November 12 WIRED report.
In a statement, Synchron emphasized that the issue involves the connecting cable rather than the Stentrode stent array itself, that no patient safety problems have been identified, and that the U.S. Food and Drug Administration did not order the pause. The company is bringing lead design and manufacturing in-house and scaling back its New York footprint while recruiting 13 engineering and lead-assembly roles in San Diego to upgrade the full Stentrode system and develop a catheter-delivered multi-region brain interface.
The pause affects Synchron's multisite studies launched in spring 2026 ahead of an FDA pivotal trial: the 10-patient U.S. INTENT study across five hospitals (Mayo Clinic Jacksonville, University at Buffalo, Mount Sinai, UPMC, and UT Southwestern) and the 10-patient Australian FOCUS-AUS trial at Royal Melbourne Hospital, while its two-hospital Toronto study (FOCUS-CAN) was listed as terminated on September 25 after enrolling one participant.
insidebci.com · Read the original ↗
More about biohacking
Neuralink Reaches 26 Brain-Implant Recipients With Outdoor Wheelchair Control and 75-WPM Speech Decoding
At least 26 clinical trial participants have received Neuralink's intracortical N1 brain-computer interface (BCI) implant as of November 2026, with recent milestones spanning outdoor powered-wheelchai...
Cognixion Launches NIH-Funded Clinical Trial of Non-Invasive EEG and AR Brain-Computer Interface
Santa Barbara neurotechnology developer Cognixion has launched CHOICE, an NIH-funded 12-week clinical trial enrolling 30 adults with amyotrophic lateral sclerosis (ALS) to evaluate its non-invasive el...
Precision Neuroscience Expands Layer 7 Cortical Brain-Computer Interface Trials to Cleveland Clinic Abu Dhabi
Following its $250 million Series D funding round, brain-computer interface developer Precision Neuroscience has signed a two-year memorandum of understanding with Cleveland Clinic Abu Dhabi (CCAD) an...